VieCure Appoints Pradip De, PhD, to the Position of Director, Translational Oncology

CHICAGO — (June 2, 2017) — VieCure (Greenwood Village, CO) announced the appointment of Dr. Pradip De to the position of Director of Translational Oncology.   Dr. De is the Senior Scientist and Head of Translational Oncology at the Avera Cancer Institute Center for Precision Oncology. He holds the position of Assistant Professor in the Department of Internal Medicine at the University of South Dakota Sanford School of Medicine.

Over the course of his 20-year career in cancer research (in industry and academia), Dr. De has authored many peer-reviewed articles, editorials, and book chapters. He has also presented his research at several international conferences with over 100 accepted abstracts. Dr. De is a regular reviewer for several leading, peer-reviewed journals, including FEBS letters, Cancer Research, Clinical Cancer Research, British Journal of Cancer, Oncologist and Molecular Cancer Therapeutics.

In his role with VieCure, and in light of his superb comprehension of oncogenic signaling pathways, Dr. De will support the development, maintenance, testing and validation of sequence-guided oncology treatment rules. These codified clinical rules enable the translation of patient specific data into actionable knowledge for physicians. VieCure has created an AI platform that produces actionable and patient-specific treatment plans in real time.

The comprehensive treatment strategies and plans address the full continuum of cancer care, including prevention, screening, diagnosis, treatment (including surgery, radiation therapy, chemotherapy, anti-hormonal therapy, targeted therapy and immunotherapy), and survivorship follow-up care. 

Dr. Fred Ashbury, Chief Scientific Officer of VieCure, highlighted Dr. De’s integral role in the creation of the codified clinical rules that power the VCureEyellation AI engine. “Dr. De’s active research program in signal translation science is world-class. Thanks to Pradip’s guidance and collaboration, we have built hundreds of rules for genomic-guided therapies to ensure our platform facilitates oncologists’ application of genomic science in real time to improve patient outcomes.”

About VieCure

We codify the world’s premier cancer guidance from clinical research centers around the world into a technology platform that considers each patient’s unique needs and supports the care team, patient and their family through diagnosis, treatment and follow-up. VieCure is headquartered in Greenwood Village, Colorado.

Topics: